Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05998213
Other study ID # NL65069.018.18
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 5, 2018
Est. completion date December 1, 2025

Study information

Verified date August 2023
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact Cyriel Ponsioen, prof.
Phone +31 20 5668278
Email c.y.ponsioen@amsterdamumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this placebo-controlled randomised multicenter trial is to evaluate the efficacy and safety of anaerobic prepared donor fecal microbiota transplantation (FMT) compared to autologous FMT in patient with ulcerative colitis. Participants will receive 4 treatments with frozen FMT via both upper and lower gastro-intestinal route (infusion via duodenal tube and enemas). Donors are selected based on microbiota profile.


Recruitment information / eligibility

Status Recruiting
Enrollment 76
Est. completion date December 1, 2025
Est. primary completion date December 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Age =18 and <70 - Ability to give informed consent - Established ulcerative colitis with known involvement of the left colon according to the Lennard-Jones criteria - Partial mayo score of = 3 and calprotectin > 250 - Full Mayo score 5-9 - Endoscopic Mayo score of =2 in either the rectum or sigmoid upon screening sigmoidoscopy - Stable dose of thiopurines or , 5-ASA, or budesonide in preceding 8 weeks. - Stable dose of budesonide in preceding 2 weeks. - Prednisone use =15mg/day in preceding 2 weeks with a mandatory taper of 5 mg per week starting from week 4. - Women need to use reliable contraceptives during participation in the study - Alkaline phosphatase > 1.5 x ULN in the subgroup of PSC/UC patients. Exclusion Criteria: - Condition leading to profound immunosuppression - For example: HIV, infectious diseases leading to immunosuppression, bone marrow malignancies - Use of systemic chemotherapy - Child-Pugh B liver cirrhosis - Anti-TNFa treatment in preceding 2 months - Vedolizumab treatment in preceding 2 months - Tofacitinib treatment in preceding 2 months - Ustekinumab treatment in preceding 2 months - Cyclosporine treatment in preceding 4 weeks - Use of Methotrexate in preceding 2 months - Prednisolone dose > 15 mg/day in preceding 2 weeks - Use of topical therapy in preceding 2 weeks - Life expectancy < 12 months - Difficulty with swallowing - Use of systemic antibiotics in preceding 4 weeks - Use of probiotic treatment in preceding 4 weeks - Positive stool cultures for common enteric pathogens (Salmonella, Shigella, Yersinia, Campylobacter, enteropathogenic e coli) - Positive C. Difficile stool test - Positive dual faeces test for pathogenic parasites e.g. Dientamoeba histolytica, Giardia Lamblia, Dientamoeba fragilis, Blastocystis hominis only if microscopically many or very many blastocysts are seen. - Positive serological test for HIV - History of surgery: - presence of a pouch - presence of stoma - Known intra-abdominal fistula - Pregnancy or women who give breastfeeding - Vasopressive medication, icu stay - Signs of ileus, diminished passage - Allergy to macrogol or substituents, eg peanuts, shellfish - Known allergy to iv gadolinium in the subgroup of patients who would be scheduled for MRI liver - Crohn's disease - Subject who has any conditions that in the opinion of the investigator, would compromise the safety of the subject or the quality of the data and is an unsuitable candidate for the study

Study Design


Intervention

Other:
Fecal microbiota transplant
Frozen FMT via duodenal tube (2 times) and enemas (4 times)

Locations

Country Name City State
Netherlands Amsterdam University Medical Center Amsterdam Noord-Holland

Sponsors (3)

Lead Sponsor Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) UMC Utrecht, University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical and endoscopic remission per adapted Mayo: stool frequency subscores (SFS) = 1, rectal bleeding subscore (RBS) =0 and endoscopic subscore = 1.
The adapted Mayo score has a minimum score of 0 and a maximum score of 9. The 3 subscores (SFS, RBS, and endoscopic subscore) have a minimum of 0 and a maximum score of 3. The adapted Mayo score does not include PGA (physician global assessment), in contrary to the full Mayo score. A higher score reflects worse outcome.
week 8
Secondary Clinical response Adapted Mayo: decrease from baseline = 2 points and = 30% plus a decrease in RBS = 1 or an absolute RBS = 1.
The adapted Mayo score has a minimum score of 0 and a maximum score of 9. The 3 subscores (SFS, RBS, and endoscopic subscore) have a minimum of 0 and a maximum score of 3. The adapted Mayo score does not include PGA (physician global assessment), in contrary to the full Mayo score.
week 8
Secondary Endoscopic response, evaluated by sigmoidoscopy •Proportion of patients with =1 point reduction in summed endoscopic Mayo score of both the rectum and sigmoid. week 8
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2